Search Results (3,393)

Background/Objective: Topical therapy remains a cornerstone in managing fungal infections due to the deep-seated nature of the pathogens and the persistence of the disease. Ketoconazole (KTZ) is a broad-spectrum antifungal agent, but its highly lipophilic nature presents considerable challenges in developing effective topical formulations. Additionally, oral KTZ has been subject to labeling restrictions and market withdrawal due to its association with severe hepatic adverse effects. This study was conducted to design, optimize, and evaluate KTZ-loaded nanolipid carriers (NLCs; KTZ-NLCs) as a delivery platform that could improve cutaneous bioavailability and enhance antifungal activity. Methods: The optimized KTZ-NLCs were further incorporated into a mucoadhesive system (KTZ-NLCs-C) through the inclusion of Carbopol^® 940 NF, aiming to improve the retention of the formulation on the skin surface. NLCs were characterized in terms of their physical appearance, particle size, polydispersity index, zeta potential, pH, viscosity, drug content, and entrapment efficiency. The optimized KTZ-NLC and KTZ-NLCs-C formulations were subsequently assessed for in vitro drug release, ex vivo skin permeation and deposition, as well as in vivo skin irritation. Results: In vitro release studies revealed that nanocarrier systems provided a sustained release of KTZ over 24 h. The ex vivo transdermal flux and permeability coefficient of KTZ from the lead KTZ-NLCs-C formulation were approximately 2.8-fold greater than those achieved with the marketed cream formulation. The in vivo skin irritation studies indicate that NLC-based formulations are suitable for topical applications. The lead formulation was stable for 90 days (the final time point evaluated) under refrigerated and room-temperature storage conditions. Conclusions: These findings suggest that the NLC-based system is a promising platform for the topical delivery of KTZ and has the potential to enhance the therapeutic outcomes for patients with superficial fungal infections. Full article

Flavonoids are a structurally diverse class of plant-derived polyphenolic compounds widely recognized for their pleiotropic biological activities, including antioxidant, anti-inflammatory, and anticancer effects. In oncology, these compounds have demonstrated the ability to modulate key signaling pathways involved in cell proliferation, apoptosis, angiogenesis, and metastasis, highlighting their potential as multitarget therapeutic agents. However, their clinical translation remains significantly limited by unfavorable pharmacokinetic properties, such as poor aqueous solubility, extensive first-pass metabolism, rapid systemic clearance, and consequently low oral bioavailability. In this context, nanotechnology has emerged as a promising strategy to overcome these limitations. This review provides a comprehensive and critical analysis of current nanocarrier-based delivery systems for flavonoids, including polymeric nanoparticles, lipid-based nanocarriers (liposomes, solid lipid nanoparticles, and nanoemulsions), micelles, and cyclodextrin complexes, emphasizing their role in improving drug stability, enhancing cellular uptake, and enabling targeted delivery to tumor tissues through both passive mechanisms, such as the enhanced permeability and retention effect, and active targeting approaches. In addition, recent in vitro and in vivo studies demonstrating the superior antitumor efficacy of nanoencapsulated flavonoids compared to free compounds are discussed. Finally, the major translational challenges, safety considerations, and future perspectives for the clinical application of flavonoid-based nanomedicines in cancer therapy are highlighted. Full article

Tobramycin is a highly hydrophilic aminoglycoside antibiotic with limited cellular permeability and negligible oral bioavailability, necessitating parenteral administration. This study aimed to develop drug delivery systems based on nano-sized colloidal assemblies (NCAs) incorporating tobramycin ion pairs to enhance its lipophilicity, potential for transition to the oral route, and antimicrobial activities. Tobramycin was ionically paired with oleic acid, lauric acid, and fluorescein and formulated into NCA preconcentrates (F1–F5) using combinations of Tween 80, DMSO, and propylene glycol. The resulting formulations formed stable nanodroplets upon dilution (9.50–16.30 nm) with narrow size distributions (polydispersity index; PDI < 0.3) and moderate negative zeta potentials (−4.99 to −11.13 mV). In vitro release studies indicated sustained drug release for ion-paired systems compared to the rapid release of free tobramycin. Cytotoxicity evaluation in Caco-2 cells demonstrated high biocompatibility at 1:10,000 and 2:10,000 dilutions, while concentration-dependent toxicity at higher doses suggested enhanced intracellular delivery. Cellular uptake studies revealed significantly higher tobramycin internalization (p < 0.001) from formulations F1–F3, with uptake values in the range of 81.76–96.14% compared to free drug, which showed zero or negligible uptake. Fluorescein-labeled formulations (F4 and F5) further confirmed enhanced uptake, demonstrating strong intracellular fluorescence. This was supported by visual observation, UV–Vis absorbance (70.5–84.8% relative to positive control), and confocal microscopy imaging. Antimicrobial activities against P. aeruginosa and S. aureus were comparable between formulations F1–F5 and free tobramycin (inhibition zones of 16–18 mm), utilizing the same tobramycin concentration in the diluting medium. These findings validate the effectiveness of the formulated NCAs in facilitating intracellular delivery of tobramycin while preserving biocompatibility and similar antimicrobial activities. Moreover, the uptake of fluorescein provides indirect evidence supporting the enhanced internalization of tobramycin in analogous ion-paired formulations. This strategy holds promise for overcoming intestinal barriers and improving oral bioavailability, potentially enabling the transition of tobramycin from parenteral to oral administration. Full article

Antimicrobial resistance and biofilm-associated contamination continue to pose critical challenges in food safety and biomedical applications, necessitating the development of advanced antimicrobial materials with enhanced efficacy, safety, and functional adaptability. Antimicrobial nanomaterials offer versatile solutions due to their tunable physicochemical properties, surface engineering capabilities, and controlled release behaviors, enabling improved antimicrobial and antibiofilm performance across diverse systems. This review highlights the main advancements in AI-assisted design of antimicrobial nanomaterials, demonstrating how data-driven approaches are increasingly used to predict antimicrobial activity, optimize synthesis parameters, model nanotoxicity, integrate multimodal datasets, and improve interpretability through explainable AI frameworks. Key findings indicate that machine learning-guided strategies and autonomous experimental platforms significantly accelerate material optimization while reducing reliance on traditional trial-and-error methods. The review further summarizes the performance and mechanisms of major antimicrobial nanomaterial systems, including metal and metal oxide nanoparticles, metal–organic frameworks, polymeric nanocarriers, nanoemulsions, and hybrid nanostructures, with emphasis on their translational applications in food preservation, antimicrobial coatings, wound healing, implant protection, and drug delivery. Despite these advances, challenges remain in data quality, model generalizability, toxicity prediction, reproducibility, and regulatory translation. AI-enabled and data-driven frameworks provide a powerful pathway for accelerating the rational design and practical implementation of next-generation antimicrobial nanomaterials. Full article

The use of environmentally friendly corrosion inhibitors in corrosive solutions has attracted considerable attention over the past few decades. However, the uncontrolled use of such inhibitors in aggressive environments can lead to a reduction in the long-term corrosion protection performance of the system. Moreover, the need for frequent re-dosing of the inhibitor increases the overall cost. One of the effective approaches for controlled and smart release of inhibitors in corrosive media is the use of nanocarriers, in which the inhibitor molecules are adsorbed onto the surface of nanoparticles and subsequently desorbed into the corrosive electrolyte through a specific release mechanism. Among the commonly used methods to obtain such eco-friendly inhibitors is the extraction of plant-based compounds, which are abundant and cost-effective. In this study, zinc oxide (ZnO) nanoparticles were green-synthesised using a plant extract and employed as nanocarriers for the controlled release of phytochemicals in 1 M HCl solution. The corrosion behaviour of carbon steel (St37) was investigated using electrochemical polarisation techniques. Results revealed that the system acts as a mixed-type inhibitor, achieving an inhibition efficiency of approximately 85% at optimal concentration, demonstrating its potential as a sustainable and cost-effective alternative for corrosion protection. Full article

Chitin deacetylases (CDAs) play important roles in the growth and development of insects. In this study, four genes encoding chitin deacetylases (BtCDAs) were identified and characterized in the genome of the whitefly Bemisia tabaci MEAM1 cryptic species through bioinformatic annotation. Phylogenetic analysis showed that insect chitin deacetylases could be divided into five groups, with no Group II, IV, or V CDAs found in B. tabaci. Investigation of the developmental expression patterns of the four BtCDAs revealed that BtCDA1, BtCDA2a, BtCDA2b, and BtCDA4 were expressed at varying levels during the egg and nymph stages, with extremely low expression levels in adults. Delivery of dsRNA targeting BtCDA1, BtCDA2a/b, and BtCDA4 to fourth-instar nymphs of B. tabaci using the nanomaterial SPc resulted in significant gene silencing and mortality. A fusion gene of the three BtCDAs was designed based on the four BtCDA genes and subjected to RNAi experiments, demonstrating that both transgenic tomato and SPc-mediated delivery of fusion gene dsRNA could silence all BtCDA genes. These preliminary results indicate that the RNAi targeting of BtCDAs leads to substantial mortality in B. tabaci, highlighting the potential of BtCDAs as effective targets for RNAi-based pest management strategies. Full article

The global prevalence of autoimmune diseases ranges from 3% to 8%, with women at a significantly higher risk than men. The core mechanisms underlying these diseases include impaired T-cell and B-cell immune tolerance, abnormal cytokine production, and aberrant activation of related signaling pathways. Conventional treatments primarily focus on suppressing immune responses, but their efficacy remains limited and they are often associated with substantial side effects. Nanomedicine leverages nanoscale materials to enable precise diagnosis and targeted therapy. Nanocarriers can penetrate biological barriers, enhance cellular uptake, and prolong circulation time in vivo, demonstrating considerable potential for drug delivery. Common nanoscale drug delivery platforms include nanoparticles, polymeric micelles, liposomes, dendrimers, mesoporous materials, hydrogels, and exosomes. Each carrier type possesses distinct characteristics in terms of drug-loading capacity, stability, responsiveness, and biocompatibility, thereby enabling targeted delivery and controlled release. This review summarizes recent advances in nano-delivery technologies for three representative chronic autoimmune diseases: diabetes mellitus (DM), inflammatory bowel disease (IBD), and rheumatoid arthritis (RA). Nano-delivery systems can improve therapeutic outcomes by optimizing drug delivery, targeting complications, and modulating the pathological microenvironment. They enhance drug bioavailability, reduce off-target and systemic adverse effects, and provide novel strategies for the precise and efficient treatment of chronic autoimmune diseases. Full article

Cancer progression is closely associated with dysregulation of apoptosis, enabling malignant cells to evade programmed cell death and develop resistance to therapy. Among the key regulators of this process, the tumor suppressor protein p53 and the Bcl-2 family of proteins play central and interconnected roles in controlling cell survival and mitochondrial integrity. In recent years, naturally occurring flavonoids have attracted considerable attention as potential modulators of these pathways due to their diverse biological activities and relatively low toxicity. This review provides a focused and integrative overview of how different subclasses of flavonoids modulate the p53–Bcl-2 signaling axis to regulate apoptosis in cancer cells. Particular emphasis is placed on the mechanistic interplay between p53 stabilization, transcriptional regulation of apoptotic targets, mitochondrial outer membrane permeabilization, and caspase activation. In contrast to previous general reviews on flavonoids and cancer, this work provides an integrated overview of evidence across multiple flavonoid subclasses and experimental cancer models, highlighting both shared and pathway-specific apoptotic responses. Experimental findings from in vitro and in vivo studies are discussed, including the effects of quercetin, kaempferol, myricetin, epigallocatechin gallate, and related compounds on cell-cycle arrest, oxidative stress, mitochondrial dysfunction, and intrinsic apoptotic signaling. Furthermore, the review examines the relationship between flavonoid chemical structure and biological activity, with particular attention to bioavailability, metabolic transformation, and strategies aimed at improving therapeutic efficacy, including structural modification and nanocarrier-based delivery systems. Despite promising preclinical findings, significant translational challenges remain, including poor pharmacokinetic properties, variability among experimental models, and limited clinical validation. Overall, flavonoids represent a promising class of bioactive compounds capable of targeting apoptosis through modulation of the p53–Bcl-2 network, and a deeper mechanistic understanding of their activity may support the development of novel targeted and combination anticancer therapies. Full article

Efficient delivery systems are essential for transporting chemotherapeutic agents to target sites, enhancing cellular uptake and reducing off-target side effects. Peptides, owing to their intrinsic biocompatibility and structural tunability, have emerged as promising carriers for delivering labile chemotherapeutics and improving pharmacokinetics and therapeutic outcomes. Along these lines, a wide variety of peptide-based delivery strategies have been developed to achieve desirable pharmaceutical properties for anticancer agents. Particularly, stimuli-responsive peptide-based nanocarriers have attracted high levels of attention due to their ability to exploit overexpressed or tumor-specific stimuli, enabling selective disassembly and controlled drug release within cancer cells. In this review, we highlight recent advances in the development of stimuli-responsive peptide nanocarriers and their applications in anticancer therapy, and discuss key challenges and future directions toward their clinical translation. Full article

Cutaneous infections and chronic inflammatory wounds remain difficult to treat because antimicrobial resistance, polymicrobial biofilms, excessive protease activity, oxidative stress, and impaired barrier repair collectively reduce the effectiveness of conventional topical therapies. Plant-derived antimicrobial peptides (AMPs) and peptide-associated bioactives offer antimicrobial, antibiofilm, immunomodulatory, and tissue reparative potential; however, their clinical translation is limited by proteolytic instability, poor stratum corneum penetration, short cutaneous residence time, formulation variability, cytotoxicity risks and limited human evidence. The key research gap is the lack of an integrated translational framework linking plant-derived peptide bioactivity with polymer engineering, advanced delivery systems, skin microenvironment biology, manufacturability, and regulatory feasibility. This review aims to critically evaluate the design principles, therapeutic mechanisms, delivery platforms, and translational barriers of plant-based peptide–polymer therapeutics for cutaneous infection and inflammation. We summarize major classes of plant-derived antimicrobial peptides, including defensins, cyclotides, thionins, hevein-like peptides, snakins, lipid transfer proteins, and knottin-type scaffolds, and examine engineering strategies such as self-assembly, aromatic N-capping, PEGylation, lipidation, dendritic architectures, and stimuli-responsive conjugation. We further discuss topical matrices, nanocarriers, liposomes, electrospun fibers, and surface-tethered biomaterials as delivery platforms for improving peptide stability, local retention, and controlled release. Finally, we identify key translational bottlenecks, including selectivity, toxicity, scalability, batch reproducibility, regulatory classification, and insufficient clinical validation. Mechanism-driven peptide optimization, quality-by-design manufacturing, standardized preclinical models, and controlled clinical trials will be essential for advancing these systems toward safe and effective dermatological therapies. Full article

Poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-b-PCL) copolymer micelles have emerged as promising drug delivery systems for enhancing the solubility and bioavailability of poorly water-soluble benzimidazole drugs. In this study, we prepared and characterized PEG-b-PCL micelles to encapsulate poorly water-soluble anthelmintics such as albendazole (ABZ) and fenbendazole (FBZ), with a focus on comparing their encapsulation behaviour, release profiles, and biological activity in cancer therapy. Drug-loaded micelles were analysed using dynamic light scattering (DLS), which revealed uniform nanosized micelles with a narrow polydispersity index (PDI). The morphology and size of both empty and drug-loaded micelles were examined using transmission electron microscopy (TEM), confirming that the micelles were spherical and consistent in size. Both drugs were efficiently encapsulated within the micellar core, demonstrating a high loading capacity. The release profiles of PEG-b-PCL micelles containing albendazole (ABZ) and fenbendazole (FBZ) at pH 7.4 were also evaluated. FBZ exhibited slower release kinetics compared to ABZ, likely due to its higher lipophilicity and stronger interactions with the hydrophobic PCL core, resulting in enhanced retention within the micelles. In contrast, ABZ had faster release kinetics. Finally, the in vitro MTT assays performed on the highly invasive triple-negative breast cancer (TNBC) cell line revealed the potential of these micelles as effective drug delivery systems. Full article

Background/Objectives: Lipid-based nanocarriers have emerged as promising systems for improving the delivery of poorly soluble drugs by enhancing stability, bioavailability, and controlled release. This work aimed to formulate solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) containing ciprofloxacin (CIP) using solvent-free procedures. Methods: The systems were extensively characterized using dynamic light scattering (DLS), transmission electron microscopy (TEM), and atomic force microscopy (AFM) to study the nanoparticles in the solid state. Furthermore, in vitro drug release was evaluated, and mathematical modeling was applied to analyze the resulting release kinetics. Additionally, storage stability was assessed at 4 °C and 25 °C over a period of 8 months. Results: The results indicated that SLN with an average size of ~50 nm (SLN 50) and NLC with mean diameters of ~25, 50, and 100 nm (NLC 25, NLC 50 and NLC 100 respectively) were successfully prepared. DLS measurements showed narrow particle size distributions (PdI ≤ 0.2) and negative zeta potentials ranging from −3.7 to −7.7 mV. Encapsulation efficiencies were remarkably high for most systems, reaching ~98% for SLN 50, NLC 50, and NLC 100, while the smallest formulation (NLC 25) showed a lower efficiency (~80%). Both TEM and AFM confirmed the formation of spherical nanoscale structures consistent with the sizes determined by DLS. Release studies revealed a strong influence of particle size on kinetics: NLC 25 exhibited rapid release (~95% within 30 min), whereas NLC 100 showed a sustained profile (<20% after 6 h). Dissolution profiles were accurately described by the Lumped-Gonzo kinetic model (R² > 0.98), enabling estimation of dissolution efficiency. Conclusions: These findings confirm that lipid-based nanocarriers can be engineered to precisely control CIP release. Full article

This study reports the plant-mediated synthesis of copper-oxide-decorated magnetic iron oxide composite (CuO@Fe₃O₄) nanoparticles using Dolomiaea costus extract and their application as nanocarriers for β-galactosidase immobilization. The fabricated nanocomposite exhibited favorable physicochemical properties, achieving an immobilization efficiency of 83%, with enhanced thermal and pH tolerance compared to the free enzyme. Kinetic analysis revealed a modest increase in Km and a 31% decrease in Vmax after immobilization, while maintaining 69% of the catalytic activity, confirming the system’s suitability for industrial lactose hydrolysis. Reusability and storage tests showed 79% retained activity after five cycles and 77% after 60 days at 4 °C. In milk hydrolysis, the immobilized enzyme achieved 77% conversion within 3 h, following pseudo-first-order kinetics. Biocompatibility was evaluated using HepG2 cells via the MTT assay. BDH, MDH, and ABC maintained high cell viability across the tested dilution range of 25–100% (v/v), indicating no detectable cytotoxic effect under the experimental conditions, whereas cisplatin showed marked cytotoxicity with an IC₅₀ of 14.98 µg/mL. These findings demonstrate that the green-synthesized CuO@Fe₃O₄ support provides a safe, reusable, and magnetically recoverable platform for β-galactosidase immobilization, offering a promising sustainable strategy for producing lactose-free dairy products. Full article

Background: Oral protein delivery is a major challenge in the field of pharmaceutical technology due to poor stability and limited permeability through intestinal barriers. Buccal delivery is a promising alternative with less restricting physiological conditions; however, low protein permeability is still a limiting factor. Multiple nanocarriers have been proposed to improve buccal protein delivery with lipid–polymer hybrid nanoparticles (LPHNs) combining the advantages of both polymeric and lipid-based systems. However, these conventional carriers rely on passive protein protection and lack adaptive release mechanisms. Objectives: This work aimed to develop and systematically optimize an ionic strength-responsive LPHN system that can minimize protein release in buccal ionic conditions while offering a triggered release in plasma after absorption. Methods: LPHNs were prepared by a two-step approach where polymeric cores of Eudragit-L100 were prepared by electrostatic complexation with Lysozyme (LYZ) followed by lipid shell formation by the ethanol injection method. Systematic optimization was performed using two-level factorial and central composite designs. Moreover, the ionic strength responsiveness and in vitro LYZ release were investigated in different ionic strength media. Results: The final optimized formulations, LPHNs and sodium deoxycholate-containing LPHNs (NaDC-LPHNs), exhibited a particle size of 257.2 ± 1.5 nm and 246 ± 5.7 nm, encapsulation efficiency of 69.89 ± 0.22% and 68.14 ± 0.16%, and high drug loading efficiency of 24.11 ± 0.06% and 23.65 ± 0.04%, respectively. Moreover, both formulations showed minimal protein release at low ionic strength (buccal-like) conditions while demonstrating a triggered release at higher ionic strength (plasma-like) conditions. Conclusions: The developed system may provide a promising smart strategy to improve buccal protein delivery by enhancing buccal protection and improving systemic delivery. Full article

Carbapenem-resistant Enterobacterales (CRE) are a major therapeutic challenge because of limited treatment options and high mortality. Despite advances in resistance-targeted therapies and pharmacokinetic (PK) optimization, treatment failure remains common. This review examines how resistance mechanisms and antibiotic exposure at the infection site jointly influence therapeutic outcomes in CRE infections. A mechanistic synthesis of evidence on carbapenem PKs, bacterial resistance, and nanoparticle (NP)-based delivery systems was performed. Based on this analysis, we propose the Pre-Target Interception Model (PTIM), which describes treatment failure as the progressive loss of active antibiotic before reaching penicillin-binding proteins. Unlike conventional approaches that focus primarily on resistance determinants or drug delivery platforms, PTIM emphasizes the factors that limit effective antibiotic exposure within infected tissues. Within this framework, nanocarrier systems are assessed according to their ability to protect antibiotics, enhance tissue penetration, and improve retention under conditions of enzymatic degradation, membrane restriction, efflux activity, and biofilm-associated diffusion barriers. However, clinical translation remains limited by manufacturing challenges, variability in NP performance, and the lack of validation in CRE-specific settings. Future progress will require quantitative measurement of antibiotic exposure at infection sites, standardized evaluation of nanocarrier performance, and validation in clinically relevant models. PTIM provides a framework for the rational development of nanomedicines designed to improve antibiotic delivery in CRE infections. Full article